Contents
Filgotinib is an immunology drug developed by Galapagos and licensed to Gilead for the treatment of rheumatoid arthritis. Filgotinib has been evaluated in multiple late-stage clinical studies, demonstrating efficacy and safety. The drug is also being evaluated by Gilead for other autoimmune indications like Crohn’s disease, psoriatic arthritis and ulcerative colitis. Galapagos plans to have greater involvement in European commercialization of Filgotinib and split the development costs with Gilead.
Timeline
No Timeline data yet.
Further Resources
Title
Author
Link
Type
Date
No Further Resources data yet.
References
Product attributes
Industry
Chemical Substance attributes
ChEMBL ID
CHEMBL3301607
CAS Registry Number
1206161-97-8
Canonical SMILES
C1CC1C(=O)NC2=NN3C(=N2)C=CC=C3C4=CC=C(C=C4)CN5CCS(=O)(=O)CC5
DSSTox ID
DTXSID80152935
UNII
3XVL385Q0M
Other attributes
Wikidata ID
